Diacomit 250 mg Норвегія - норвезька - Statens legemiddelverk

diacomit 250 mg

abacus medicine a/s - stiripentol - kapsel, hard - 250 mg

Diacomit 500 mg Норвегія - норвезька - Statens legemiddelverk

diacomit 500 mg

abacus medicine a/s - stiripentol - kapsel, hard - 500 mg

Emgality 120 mg Норвегія - норвезька - Statens legemiddelverk

emgality 120 mg

abacus medicine a/s - galkanezumab - injeksjonsvæske, oppløsning i ferdigfylt penn - 120 mg

Adempas 0.5 mg Норвегія - норвезька - Statens legemiddelverk

adempas 0.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 0.5 mg

Adempas 1 mg Норвегія - норвезька - Statens legemiddelverk

adempas 1 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 1 mg

Adempas 1.5 mg Норвегія - норвезька - Statens legemiddelverk

adempas 1.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 1.5 mg

Adempas 2 mg Норвегія - норвезька - Statens legemiddelverk

adempas 2 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 2 mg

Adempas 2.5 mg Норвегія - норвезька - Statens legemiddelverk

adempas 2.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 2.5 mg

Opsumit 10 mg Норвегія - норвезька - Statens legemiddelverk

opsumit 10 mg

abacus medicine a/s - macitentan - tablett, filmdrasjert - 10 mg

Thiotepa Riemser Європейський Союз - норвезька - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.